229 related articles for article (PubMed ID: 27321186)
1. PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.
Wang Y; Justilien V; Brennan KI; Jamieson L; Murray NR; Fields AP
Oncogene; 2017 Jan; 36(4):534-545. PubMed ID: 27321186
[TBL] [Abstract][Full Text] [Related]
2. Recurrent copy number gains drive PKCι expression and PKCι-dependent oncogenic signaling in human cancers.
Liu Y; Justilien V; Fields AP; Murray NR
Adv Biol Regul; 2020 Dec; 78():100754. PubMed ID: 32992230
[TBL] [Abstract][Full Text] [Related]
3. PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis.
Wang Y; Hill KS; Fields AP
Mol Cancer Res; 2013 Dec; 11(12):1624-35. PubMed ID: 24174471
[TBL] [Abstract][Full Text] [Related]
4. PRKCI promotes immune suppression in ovarian cancer.
Sarkar S; Bristow CA; Dey P; Rai K; Perets R; Ramirez-Cardenas A; Malasi S; Huang-Hobbs E; Haemmerle M; Wu SY; McGuire M; Protopopov A; Jiang S; Liu JF; Hirsch MS; Chang Q; Lazar AJ; Sood AK; Drapkin R; DePinho R; Draetta G; Chin L
Genes Dev; 2017 Jun; 31(11):1109-1121. PubMed ID: 28698296
[TBL] [Abstract][Full Text] [Related]
5. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation.
Justilien V; Fields AP
Oncogene; 2009 Oct; 28(41):3597-607. PubMed ID: 19617897
[TBL] [Abstract][Full Text] [Related]
6. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
[TBL] [Abstract][Full Text] [Related]
7. Addiction to protein kinase Cɩ due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer.
Rehmani H; Li Y; Li T; Padia R; Calbay O; Jin L; Chen H; Huang S
Signal Transduct Target Ther; 2020 Aug; 5(1):140. PubMed ID: 32820156
[TBL] [Abstract][Full Text] [Related]
8. Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer.
Wang P; Zhang H; Yang J; Li Z; Wang Y; Leng X; Ganapathy S; Isakson P; Chen C; Zhu T
J Cell Physiol; 2020 Jan; 235(1):408-420. PubMed ID: 31230347
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma.
Liu Y; Yin N; Wang X; Khoor A; Sambandam V; Ghosh AB; Fields ZA; Murray NR; Justilien V; Fields AP
Cell Rep; 2020 Jan; 30(3):771-782.e6. PubMed ID: 31968252
[TBL] [Abstract][Full Text] [Related]
10. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.
Justilien V; Walsh MP; Ali SA; Thompson EA; Murray NR; Fields AP
Cancer Cell; 2014 Feb; 25(2):139-51. PubMed ID: 24525231
[TBL] [Abstract][Full Text] [Related]
11. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.
Regala RP; Weems C; Jamieson L; Copland JA; Thompson EA; Fields AP
J Biol Chem; 2005 Sep; 280(35):31109-15. PubMed ID: 15994303
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor Sp1 is upregulated by PKCι to drive the expression of YAP1 during pancreatic carcinogenesis.
Yang J; Wang J; Zhang H; Li C; Chen C; Zhu T
Carcinogenesis; 2021 Apr; 42(3):344-356. PubMed ID: 33146712
[TBL] [Abstract][Full Text] [Related]
13. Atypical protein kinase C induces cell transformation by disrupting Hippo/Yap signaling.
Archibald A; Al-Masri M; Liew-Spilger A; McCaffrey L
Mol Biol Cell; 2015 Oct; 26(20):3578-95. PubMed ID: 26269582
[TBL] [Abstract][Full Text] [Related]
14. Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
Cho SY; Kim K; Park MS; Jang MY; Choi YH; Han S; Shin HM; Chung C; Han HY; Yang JB; Ko YB; Yoo HJ
Oncol Rep; 2017 May; 37(5):2620-2632. PubMed ID: 28339095
[TBL] [Abstract][Full Text] [Related]
15. Atypical protein kinase Cι (PKCι) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKCι-SKP2-AKT pathway.
Liu SG; Wang BS; Jiang YY; Zhang TT; Shi ZZ; Yang Y; Yang YL; Wang XC; Lin DC; Zhang Y; Yang H; Cai Y; Zhan QM; Wang MR
Mol Cancer Res; 2011 Apr; 9(4):390-402. PubMed ID: 21310827
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation.
Justilien V; Jameison L; Der CJ; Rossman KL; Fields AP
J Biol Chem; 2011 Mar; 286(10):8149-8157. PubMed ID: 21189248
[TBL] [Abstract][Full Text] [Related]
17. PKCiota promotes ovarian tumor progression through deregulation of cyclin E.
Nanos-Webb A; Bui T; Karakas C; Zhang D; Carey JP; Mills GB; Hunt KK; Keyomarsi K
Oncogene; 2016 May; 35(19):2428-40. PubMed ID: 26279297
[TBL] [Abstract][Full Text] [Related]
18. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
Butler AM; Scotti Buzhardt ML; Erdogan E; Li S; Inman KS; Fields AP; Murray NR
Oncotarget; 2015 Jun; 6(17):15297-310. PubMed ID: 25915428
[TBL] [Abstract][Full Text] [Related]
19. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.
Hsu YL; Hung JY; Chou SH; Huang MS; Tsai MJ; Lin YS; Chiang SY; Ho YW; Wu CY; Kuo PL
Oncogene; 2015 Jul; 34(31):4056-68. PubMed ID: 25381822
[TBL] [Abstract][Full Text] [Related]
20. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
Fields AP; Frederick LA; Regala RP
Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
